全文获取类型
收费全文 | 464篇 |
免费 | 50篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 4篇 |
妇产科学 | 5篇 |
基础医学 | 169篇 |
口腔科学 | 3篇 |
临床医学 | 47篇 |
内科学 | 126篇 |
皮肤病学 | 20篇 |
神经病学 | 12篇 |
特种医学 | 7篇 |
外科学 | 18篇 |
综合类 | 23篇 |
预防医学 | 17篇 |
眼科学 | 1篇 |
药学 | 41篇 |
肿瘤学 | 20篇 |
出版年
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2018年 | 4篇 |
2017年 | 1篇 |
2016年 | 5篇 |
2015年 | 2篇 |
2014年 | 2篇 |
2013年 | 6篇 |
2012年 | 24篇 |
2011年 | 21篇 |
2010年 | 15篇 |
2009年 | 11篇 |
2008年 | 27篇 |
2007年 | 37篇 |
2006年 | 42篇 |
2005年 | 40篇 |
2004年 | 37篇 |
2003年 | 37篇 |
2002年 | 40篇 |
2001年 | 30篇 |
2000年 | 15篇 |
1999年 | 14篇 |
1998年 | 4篇 |
1997年 | 6篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 4篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1991年 | 3篇 |
1990年 | 6篇 |
1989年 | 4篇 |
1988年 | 6篇 |
1987年 | 7篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 9篇 |
1982年 | 1篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1972年 | 1篇 |
排序方式: 共有515条查询结果,搜索用时 14 毫秒
31.
32.
33.
34.
35.
In an unusual paradox, asthmatics who are chronically treated with bronchodilating beta-agonists sometimes experience a worsening of their condition. A new study describes one possible mechanism and reveals a potential new therapeutic target in the treatment of asthma. 相似文献
36.
37.
38.
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) provides unique information about the metabolic behavior of the malignant tumors, independent of morphological criteria. This technique is more sensitive in imaging lymphoma prior to therapy than conventional computed tomography (CT) imaging and Ga-67 scintigraphy. FDG-PET performed in patients with lymphoma offers important additional information on the presence of viable disease in residual masses of the tumor. It is also of great value in assessing therapy response in patients with Hodgkin s disease and non-Hodgkin s lymphoma, because of its ability to differentiate between fibrosis and active tumor. More studies are needed to assess the value of this method in long-term follow-up. In our institution this method is mostly used for clarification of residual post-therapy abnormalities that fall under the category of unconfirmed/uncertain complete remission. Our preliminary data on 14 patients indicate that this non-invasive, metabolic imaging is superior to CT and other conventional diagnostic methods in the post-therapy staging of lymphoma. 相似文献
39.
Drazen JM 《The New England journal of medicine》2002,346(17):1262-1263
40.
Significant variability in response to inhaled corticosteroids for persistent asthma 总被引:12,自引:0,他引:12
Szefler SJ Martin RJ King TS Boushey HA Cherniack RM Chinchilli VM Craig TJ Dolovich M Drazen JM Fagan JK Fahy JV Fish JE Ford JG Israel E Kiley J Kraft M Lazarus SC Lemanske RF Mauger E Peters SP Sorkness CA;Asthma Clinical Research Network of the National Heart Lung Blood Institute 《The Journal of allergy and clinical immunology》2002,109(3):410-418
BACKGROUND: A clinical model is needed to compare inhaled corticosteroids (ICSs) with respect to efficacy. OBJECTIVE: The purpose of this investigation was to compare the relative beneficial and systemic effects in a dose-response relationship for 2 ICSs. METHODS: A 24-week, parallel, open-label, multicenter trial examined the benefit-risk ratio of 2 ICSs in persistent asthma. Benefit was assessed by improvements in FEV(1) and PC(20); risk was assessed by overnight plasma cortisol suppression. Thirty subjects were randomized to either beclomethasone dipropionate (BDP) 168, 672, and 1344 microg/day (n = 15) or fluticasone propionate (FP) 88, 352, and 704 microg/day (n = 15), both administered by means of a metered dose inhaler (MDI) with chlorofluorocarbon propellant via a spacer, in 3 consecutive 6-week intervals; this was followed by 3 weeks of FP dry powder inhaler (DPI) 2000 microg/day. RESULTS: Maximum FEV(1) response occurred with the low dose for FP-MDI and the medium dose for BDP-MDI and was not further increased by treatment with FP-DPI. Near-maximum methacholine PC(20) improvement occurred with the low dose for FP-MDI and the medium dose for BDP-MDI. Both BDP-MDI and FP-MDI caused dose-dependent cortisol suppression. Responsiveness to ICS treatment was found to vary markedly among subjects. Good (>15%) FEV(1) response, in contrast to poor (<5%) response, was found to be associated with high exhaled nitric oxide (median, 17.6 vs 11.1 ppb), high bronchodilator reversibility (25.2% vs 8.8%), and a low FEV(1)/forced vital capacity ratio (0.63 vs 0.73) before treatment. Excellent (>3 doubling dilutions) improvement in PC(20), in contrast to poor (<1 doubling dilution) improvement, was found to be associated with high sputum eosinophil levels (3.4% vs 0.1%) and older age at onset of asthma (age, 20-29 years vs <10 years). CONCLUSIONS: Near-maximal FEV(1) and PC(20) effects occurred with low-medium dose for both ICSs in the subjects studied. High-dose ICS therapy did not significantly increase the efficacy measures that were evaluated, but it did increase the systemic effect measure, overnight cortisol secretion. Significant intersubject variability in response occurred with both ICSs. It is possible that higher doses of ICSs are necessary to manage more severe patients or to achieve goals of therapy not evaluated in this study, such as prevention of asthma exacerbations. 相似文献